Matthew K. Fust, Director at Crinetics Pharmaceuticals, Inc. (CRNX), sold 47,500 shares at $45.50 ($2.1M) on 2024-03-20, disclosed to the SEC on 2024-03-22.
Scheduled sale ($2.1M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $43.57 | 12,500 | $545K | 25.9% |
| 2 | $43.58 | 17,500 | $763K | 36.3% |
| 3 | $45.50 | 17,500 | $796K | 37.9% |
| Total | $44.28 avg | 47,500 | $2.1M | 100% |
| Filing → |
| RARE | SELL | 2024-03-11 | $859K | — | Filing → |
| CRNX | SELL | 2022-07-15 | $119K | — | Filing → |
| ATRA | SELL | 2021-11-05 | $260K | — | Filing → |